{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T05:27:20Z","timestamp":1767245240249,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bbmt.2020.07.016","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T02:49:48Z","timestamp":1595472588000},"page":"2040-2046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma"],"prefix":"10.1016","volume":"26","author":[{"given":"Alexandra","family":"Gomez-Arteaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond E.","family":"Baser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josel D.","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parastoo B.","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnab","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar B.","family":"Lahoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian C.","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guenther","family":"Koehne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.07.016_bib0001","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12935-018-0553-8","article-title":"Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017","volume":"18","author":"Yin","year":"2018","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0002","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3324\/haematol.2018.200881","article-title":"Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life","volume":"104","author":"Greil","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0003","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3324\/haematol.2018.200253","article-title":"Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma","volume":"104","author":"Maffini","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0004","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/bmt.2012.142","article-title":"Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory\/relapsed myeloma patients","volume":"48","author":"Kr\u00f6ger","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0005","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1182\/blood-2011-03-339945","article-title":"Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma","volume":"117","author":"Giaccone","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0006","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/leu.2016.101","article-title":"Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party","volume":"30","author":"Sobh","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0007","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0008","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.bbmt.2019.04.026","article-title":"Response to novel drugs before and after allogeneic stem cell transplantation in patients with relapsed multiple myeloma","volume":"25","author":"L\u00f3pez-Corral","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0009","doi-asserted-by":"crossref","unstructured":"Costa LJ, Iacobelli S, Pasquini MC, et al. Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. Bone Marrow Transplant. 2020; doi: 10.1038\/s41409-020-0887-4, Online ahead of print.","DOI":"10.1038\/s41409-020-0887-4"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bbmt.2019.08.023","article-title":"Presalvage International Staging System stage and other important outcome associations in CD34+-selected allogeneic hematopoietic stem cell transplantation for multiple myeloma","volume":"26","author":"Bryant","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0011","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bbmt.2015.08.025","article-title":"CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma","volume":"22","author":"Smith","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0012","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0013","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.1995.13.6.1312","article-title":"Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma","volume":"13","author":"Gahrton","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0014","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/bmt.2017.183","article-title":"Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients","volume":"52","author":"Montefusco","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0015","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0016","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0017","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3324\/haematol.2013.084350","article-title":"Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution","volume":"98","author":"Tovar","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0018","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0020","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.clml.2017.02.018","article-title":"High-risk multiple myeloma: definition and management","volume":"17S","author":"Joseph","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0021","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/leu.2017.331","article-title":"Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time","volume":"32","author":"Kumar","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0022","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbmt.2020.02.020","article-title":"Relapse after allogeneic hematopoietic cell transplantation for multiple myeloma: survival outcomes and factors influencing them","volume":"26","author":"Chhabra","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0023","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbmt.2017.10.024","article-title":"Autologous\/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: comparison of long-term postrelapse survival","volume":"24","author":"Htut","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0024","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bbmt.2019.11.018","article-title":"Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long-term follow-up results from the Blood and Marrow Transplant Clinical Trials Network 0102 trial","volume":"26","author":"Giralt","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0025","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood.V98.4.934","article-title":"T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect","volume":"98","author":"Alyea","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0026","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0027","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1182\/blood-2003-07-2559","article-title":"Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens","volume":"103","author":"Bellucci","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0028","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2000.18.16.3031","article-title":"Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome","volume":"18","author":"Lokhorst","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0029","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/bbmt.2002.v8.pm12171481","article-title":"Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation","volume":"8","author":"Baron","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0030","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2012-06-435040","article-title":"WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions","volume":"121","author":"Tyler","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0031","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/bmt.2016.23","article-title":"Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS","volume":"51","author":"Dahi","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0032","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/leu.2014.145","article-title":"Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis","volume":"28","author":"Stern","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0033","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.bmt.1702187","article-title":"Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion","volume":"25","author":"Orsini","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0034","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.bbmt.2017.05.006","article-title":"Haploidentical allogeneic hematopoietic cell transplantation for multiple myeloma using post-transplantation cyclophosphamide graft-versus-host disease prophylaxis","volume":"23","author":"Castagna","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0035","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/ejh.12758","article-title":"Outcome of allogeneic transplantation in newly diagnosed and relapsed\/refractory multiple myeloma: long-term follow-up in a single institution","volume":"97","author":"Franssen","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0036","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","article-title":"Autologous\/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study","volume":"121","author":"Gahrton","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2012.10.004","article-title":"Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a phase I\/II dose-finding study","volume":"41","author":"Wolschke","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0038","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood.V128.22.4585.4585","article-title":"Immune biomarkers identify sustained quantitative and functional immune reconstitution in the setting of adjunctive lenalidomide following T-depleted RIC-allo SCT for multiple myeloma","volume":"128","author":"Cook","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0039","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.exphem.2009.03.008","article-title":"Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma","volume":"37","author":"Kr\u00f6ger","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0040","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/sj.bmt.1705982","article-title":"Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome","volume":"41","author":"Minnema","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0041","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/sj.bmt.1704713","article-title":"Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome","volume":"34","author":"Zeiser","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0042","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/sj.leu.2404085","article-title":"Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients","volume":"20","author":"P\u00e9rez-Sim\u00f3n","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0043","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.bbmt.2016.08.024","article-title":"Allogeneic hematopoietic cell transplantation in multiple myeloma: focus on longitudinal assessment of donor chimerism, extramedullary disease, and high-risk cytogenetic features","volume":"22","author":"Rasche","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.016_bib0044","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41409-019-0525-1","article-title":"Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT","volume":"55","author":"Gonzalez-Rodriguez","year":"2020","journal-title":"Bone Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387912030447X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387912030447X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:11:47Z","timestamp":1761059507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387912030447X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S108387912030447X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.016","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}